Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab and Telotristat Ethyl in Advanced Neuroendocrine Tumors and Carcinoid Syndrome
NCT04776876Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of retifanlimab in Neuroendocrine Neoplasm (NEN), Carcinoid Syndrome (CS), sponsored by University of Texas MD Anderson Cancer Center. Planned start Mar 2021; status: withdrawn.
02
Drugs
retifanlimab
03
Conditions
Neuroendocrine Neoplasm (NEN)Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT04776876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776876.